EBR Online 2016: Type 2 Diabetes
EBR Online 2016: Type 2 Diabetes
Unlike other board preparation meetings, the Endocrine Society's Board Review Course offers a comprehensive mock-exam format, with case-based ABIM-style questions forming the bulk of the presentations. Each section follows the ABIM blueprint for the board exam, covering the breadth and depth of the certification/recertification examination. But you won't just get a right or wrong answer—each case will be discussed in detail, with the correct and incorrect answer options reviewed. You'll also have the opportunities to review questions asked to the faculty, compare results from other participants, and read detailed answer explanations, references, and a customized score report.
This continuing medical education activity should be of substantial interest to endocrinologists, internists, and endocrine fellows preparing for the board examination or recertification; or endocrinologists and other health care practitioners seeking a review in endocrinology.
Upon completion of this and the Type 1 Diabetes Board Review educational activity, learners will be able to:
- Evaluate clinical practice guidelines for the management of diabetes and its comorbidities and predict how these may evolve in light of new data and clinical experience
- Initiate effective treatment programs that integrate multiple therapies, including oral medications and insulin regimens
- Recognize and treat hyperglycemia as an independent risk factor for predicting cardiovascular events and mortality
- Define medically significant weight loss and its impact on glycemic parameters
- Recognize the adverse outcomes associated with hypoglycemia and ways to prevent hypoglycemic events, with particular attention to selection of medical therapies and matching the anti-hyperglycemic regimen to nutritional intake
- Recognize the causes and risk of current hypoglycemia and hypoglycemia unawareness
- Utilize continuous glucose monitoring data to make clinical decisions
- Utilize the latest study findings to determine the best treatment course in gestational diabetes mellitus
- Diagnose skin lesions associated with diabetes mellitus
- Recognize the progression of beta-cell dysfunction in the pathophysiology of Type 2 diabetes
- Develop a treatment strategy for diabetes patients in a hospital setting
Endocrine Board Review Chair
David S. Cooper, MD – The Johns Hopkins University School of Medicine
Richard J. Auchus, MD, PhD – University of Michigan
Carolyn B. Becker, MD – Brigham and Women's Hospital
Rhonda M. Bentley-Lewis, MD, MMSc – Massachusetts General Hospital
Daniel H. Bessesen, MD – University of Colorado School of Medicine
Andrea D. Coviello, MD – Boston University School of Medicine
Serge A. Jabbour, MD – Thomas Jefferson University Sidney Kimmel Medical College
Mark E. Molitch, MD – Northwestern University Feinberg School of Medicine
Elizabeth N. Pearce, MD, MSc – Boston University School of Medicine
Margaret E. Wierman, MD – University of Colorado School of Medicine
Abbie L. Young, MS, CGC, ELS(D)
The faculty, committee members, and staff who are in a position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Richard J. Auchus, MD, PhD: Contracted Research, Atterocor Therapeutics, Strongbridge Biopharma; Contracted Research & Consultant, Novartis Pharmaceuticals; Consultant, Bluebird Bio, Corcept Therapeutics, Innocrin Pharmaceuticals, Ipsen Pharmaceuticals, Janssen Pharmaceuticals, Pfizer, Inc., Tokai Pharmaceuticals; Scientific Advisory Board, Laboratory Corporation of America, Orphagen Pharmaceuticals
Rhonda M. Bentley-Lewis, MD, MMSc: Consultant, Merck & Co.; Research Support, Sanofi; Research Support (Spouse), Novartis Pharmaceuticals
Daniel H. Bessesen, MD: Data Safety Monitoring Board Member, Enteromedics Inc.
Andrea D. Coviello, MD: Speaker, Novo Nordisk Inc.
Serge A. Jabbour, MD: Consultant, AstraZeneca, Eli Lilly & Co., Janssen Pharmaceuticals
Mark E. Molitch, MD: Consultant, Corcept, Eli Lilly & Co., Pfizer; Consultant and Investigator, Ipsen Pharmaceuticals, Novartis Pharmaceuticals, Novo Nordisk Inc.
The following faculty reported no relevant financial relationships: Carolyn B. Becker, MD, MBBS; David S. Cooper, MD; Elizabeth N. Pearce, MD, MSc; Margaret E. Wierman, MD
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
- 1.75 AMA PRA Category 1 Credits™
- 1.75 ABIM MOC II
- 1.75 CME Certificate of Participation